The 12 month open label extension trial of Patisiran for ATTRv-PN continued to demonstrate the benefits and safety profile of this RNAi.113Also, this study emphasized the importance of early treatment to halt or reverse the progression of the polyneuropathy, malnutrition, and quality of life impairment.113Patisiran has been approved by ANVISA for the treatment of ATTR-FAP but so far has not been incorporated at SUS. This evidence concerns the gene FAP and poikiloderma with neutropenia.